Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Food Effect of GSK3179106 in Healthy Volunteers
NCT02727283Phase 1Completed
- Sponsor
- GSK
- Start
- Nov 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3179106 in irritable bowel syndrome (IBS) (2 cohorts), sponsored by GSK. Primary endpoints: Number of subjects with adverse events and clinical observations up to 10 weeks, Assessment of physical examination findings up to 10 weeks and 6 more. Started Nov 2015; status: completed.
02
Drugs
GSK3179106
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT02727283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02727283.